Xencor Dirección

Dirección controles de criterios 2/4

El CEO de Xencor's es Bassil Dahiyat , nombrado en Aug 1997, tiene una permanencia de 26.67 años. compensación anual total es $7.71M, compuesta por 8.7% salario y 91.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.4% de las acciones de la empresa, por valor de €4.36M. La antigüedad media del equipo directivo y de la junta directiva es de 2.3 años y 7 años, respectivamente.

Información clave

Bassil Dahiyat

Chief Executive Officer (CEO)

US$8.0m

Compensación total

Porcentaje del salario del CEO	8.8%
Permanencia del CEO	26.8yrs
Participación del CEO	0.4%
Permanencia media de la dirección	2.3yrs
Promedio de permanencia en la Junta Directiva	7.1yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Bassil Dahiyat en comparación con los beneficios de Xencor?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$133m
Dec 31 2023	US$8m	US$700k	-US$126m
Sep 30 2023	n/a	n/a	-US$119m
Jun 30 2023	n/a	n/a	-US$128m
Mar 31 2023	n/a	n/a	-US$140m
Dec 31 2022	US$8m	US$670k	-US$55m
Sep 30 2022	n/a	n/a	US$30m
Jun 30 2022	n/a	n/a	US$22m
Mar 31 2022	n/a	n/a	US$109m
Dec 31 2021	US$5m	US$625k	US$83m
Sep 30 2021	n/a	n/a	-US$4m
Jun 30 2021	n/a	n/a	US$24m
Mar 31 2021	n/a	n/a	-US$64m
Dec 31 2020	US$4m	US$600k	-US$69m
Sep 30 2020	n/a	n/a	-US$83m
Jun 30 2020	n/a	n/a	-US$80m
Mar 31 2020	n/a	n/a	-US$61m
Dec 31 2019	US$4m	US$567k	US$27m
Sep 30 2019	n/a	n/a	US$36m
Jun 30 2019	n/a	n/a	US$49m
Mar 31 2019	n/a	n/a	US$39m
Dec 31 2018	US$4m	US$550k	-US$70m
Sep 30 2018	n/a	n/a	-US$45m
Jun 30 2018	n/a	n/a	-US$71m
Mar 31 2018	n/a	n/a	-US$53m
Dec 31 2017	US$5m	US$525k	-US$38m

Compensación vs. Mercado: La compensación total de Bassil($USD7.71M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD1.29M).

Compensación vs. Ingresos: La compensación de Bassil ha aumentado mientras la empresa no es rentable.

CEO

Bassil Dahiyat (53 yo)

26.8yrs

Permanencia

US$7,965,955

Compensación

Dr. Bassil I. Dahiyat, Ph D., Co-founded Xencor, Inc. in August 1997 and has been its President and Chief Executive Officer since February 2005. Dr. Dahiyat serves as an Independent Director at Terray Ther...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Bassil Dahiyat	Co-Founder	26.8yrs	US$7.97m	0.40% $ 4.8m
John Desjarlais	Executive VP of Research & Chief Scientific Officer	9.8yrs	US$3.21m	0.23% $ 2.8m
Celia Eckert	Senior VP	4.7yrs	US$2.02m	0.030% $ 369.5k
Nancy Valente	Executive VP & Chief Development Officer	less than a year	US$5.35m	0.015% $ 183.1k
Bart Cornelissen	Senior VP & CFO	less than a year	sin datos	sin datos
Charles Liles	Associate Director and Head of Corporate Communications & Investor Relations	no data	sin datos	sin datos
Jennifer Sandoz	Senior VIce President of Human Resources	2.8yrs	sin datos	sin datos
Jeremy Grunstein	Senior Vice President of Business Development	2.3yrs	sin datos	sin datos
Kirk Rosemark	Senior Vice President of Regulatory Affairs & Quality Assurance	2.3yrs	sin datos	sin datos
Eric Kowack	Senior Vice President of Program Leadership & Alliance Management	1.3yrs	sin datos	sin datos
Dane Leone	Senior VP of Corporate Strategy	less than a year	sin datos	sin datos

2.3yrs

Permanencia media

58yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de XE9 se considera experimentado (2.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Bassil Dahiyat	Co-Founder	26.8yrs	US$7.97m	0.40% $ 4.8m
Richard Ranieri	Independent Director	6.4yrs	US$347.02k	0% $ 0
Alan Montgomery	Independent Director	9.2yrs	US$384.19k	0% $ 0
Kevin Gorman	Independent Director	7.1yrs	US$342.50k	0% $ 0
Jeffrey Ravetch	Member of Scientific Advisory Board	14.9yrs	sin datos	sin datos
Ellen Feigal	Independent Director	5.5yrs	US$348.00k	0% $ 0
Kurt Gustafson	Independent Director	9.8yrs	US$346.50k	0.0097% $ 118.4k
Dagmar Rosa-Bjorkeson	Independent Director	4.4yrs	US$346.25k	0% $ 0
Barbara Klencke	Independent Director	less than a year	US$467.35k	sin datos

7.1yrs

Permanencia media

66yo

Promedio de edad

Junta con experiencia: La junta directiva de XE9 se considera experimentada (7 años de antigüedad promedio).

Xencor Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Xencor Appoints Bart Cornelissen as Senior Vice President

Co-Founder recently sold €270k worth of stock

Xencor, Inc. Appoints Dane Leone as Senior Vice President, Corporate Strategy

John J. Kuch to Retire as Chief Financial Officer of Xencor, Inc. in March 2024

Xencor Announces Planned Retirement of Senior Vice President John Kuch

Xencor, Inc. Appoints Barbara J. Klencke to Board of Directors

Recent updates

First quarter 2024 earnings released: US$1.11 loss per share (vs US$1.02 loss in 1Q 2023)

New minor risk - Shareholder dilution

Xencor Appoints Bart Cornelissen as Senior Vice President

Co-Founder recently sold €270k worth of stock

New minor risk - Profitability

Full year 2023 earnings released: US$2.08 loss per share (vs US$0.93 loss in FY 2022)

Xencor, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Xencor, Inc. Appoints Dane Leone as Senior Vice President, Corporate Strategy

Third quarter 2023 earnings released: US$0.40 loss per share (vs US$0.55 loss in 3Q 2022)

Xencor, Inc. to Report Q3, 2023 Results on Nov 07, 2023

John J. Kuch to Retire as Chief Financial Officer of Xencor, Inc. in March 2024

Xencor Announces Planned Retirement of Senior Vice President John Kuch

Xencor, Inc. Appoints Barbara J. Klencke to Board of Directors

Second quarter 2023 earnings released: US$0.37 loss per share (vs US$0.57 loss in 2Q 2022)

Xencor, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Xencor, Inc. Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress

Insufficient new directors

First quarter 2023 earnings released: US$1.02 loss per share (vs US$0.40 profit in 1Q 2022)

Co-Founder recently sold €172k worth of stock

Full year 2022 earnings released: US$0.93 loss per share (vs US$1.42 profit in FY 2021)

Xencor, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Senior VP & Chief Medical Officer recently sold €95k worth of stock

Xencor, Inc. Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma At the American Society of Hematology Annual Meeting

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$0.69 loss in 3Q 2021)

Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study

Xencor, Inc. to Report Q3, 2022 Results on Nov 07, 2022

High number of new directors

Xencor, Inc. to Present Seven Posters on Multiple Clinical Trials and Research-Stage Programs At the SITC Annual Meeting

High number of new directors

Xencbor, Inc. Announces the Appointment of Nancy Valente to Its Board of Directors

Second quarter 2022 earnings released: US$0.57 loss per share (vs US$0.90 profit in 2Q 2021)

Xencor, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Investor sentiment improved over the past week

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell 2000 Growth-Defensive Index

Investor sentiment improved over the past week

Xencor, Inc. Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors

First quarter 2022 earnings released: EPS: US$0.40 (vs US$0.043 loss in 1Q 2021)

Co-Founder recently sold €65k worth of stock

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Xencor, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting

Zenas BioPharma Limited acquired Exclusive worldwide rights to Obexelimab from Xencor, Inc. (NasdaqGM:XNCR).

Third quarter 2021 earnings released: US$0.69 loss per share (vs US$0.22 loss in 3Q 2020)

Director Yujiro Hata has joined 3rd company board

Second quarter 2021 earnings released: EPS US$0.90 (vs US$0.61 loss in 2Q 2020)

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell 3000E Value Index

Sotrovimab Receives U.S. FDA Emergency Use Authorization for the Treatment of COVID-19

First quarter 2021 earnings released: US$0.043 loss per share (vs US$0.14 loss in 1Q 2020)

Xencor, Inc. Doses First Subject in Phase 1 Study of XMAB®564, an Engineered IL-2 Cytokine in Development for Autoimmune Diseases

Co-Founder recently sold €106k worth of stock

Xencor and UCLA Enter Collaboration to Discover and Develop Novel XmAb® Therapeutics

Full year 2020 earnings released: US$1.21 loss per share (vs US$0.47 profit in FY 2019)

Revenue beats expectations

Xencor, Inc. to Report Q4, 2020 Results on Feb 23, 2021

New 90-day high: €42.20

Xencor, Inc. and The University of Texas MD Anderson Cancer Center Enter Strategic Collaboration to Develop Novel T Cell-Engaging Bispecific Antibodies for Potential Treatment of Patients with Cancer

New 90-day high: €38.20

Senior VP & Chief Medical Officer recently sold €135k worth of stock

Miragen Therapeutics, Inc. Enters Technology License Agreement with Xencor, Inc

New 90-day high: €37.20

Xencor, MorphoSys AG and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab

Xencor Presents Updated Data From the DUET-2 Phase 1 Study of XmAb20717, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting

Revenue misses expectations

Third quarter 2020 earnings released: US$0.22 loss per share

Xencor to Present Data from Phase 1 Study of Vibecotamab in Acute Myeloid Leukemia At the 2020 Ash Annual Meeting

Xencor, Inc. to Report Q3, 2020 Results on Nov 05, 2020

Xencor, Inc. to Present Data from the Phase 1 Study of XmAb 20717 and Three Research Programs at the SITC Annual Meeting

Xencor, Inc. Presents Initial Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at Nanets’ Multidisciplinary Net Medical Virtual Symposium

New 90-day high - €31.00